Published : 03/02/2020 - Categories : News
Since the beginning of the year, studies of new potential drugs to defeat the coronavirus have increased. Multiple tests are conducted in a remarkable timeline in order to come up with the most efficient drugs to treat patients infected by this fast spreading virus.
Alsachim has synthetised all the standards for your covid-19 research.
- [U-Ring-13C6]-Remdesivir (C8845)
- GS 441524 / Remdesivir triphosphate (Remdesivir metabolite)
- GS 441524 / Remdesivir active metabolite
- EIDD2801 (Opaganib)
- [13C6]-EIDD1931 (13C6 Opaganib)
- [13C 2H 15N]-Favipiravir
- [13C 2H3]-Azithromicin
- [13C,2H3]-Oseltamivir acid
- [13C6]-Nafamostat mesylate
- Nafamostat mesylate
Research to fight the Coronavirus
Two trials were expedited following the recommendation of the World Health Organization (WHO) experts. The use of a combination of two antiviral drugs Lopinavir and Ritonavir as a potential drug to treat the coronavirus disease is one of these trials. This combination has already proved its efficacy for the treatment of HIV Infections.
The second drug in trials is Remdesivir, this antiviral has been previously tested in humans with Ebola virus disease and has shown promise in animal models for treating Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS) which are caused by other coronaviruses. Scientists believe now that this antiviral can actually have promising results in treating the covid-19. As preliminary studies have already been done, the phase III clinical trials are now on going and results are expected in the upcoming weeks.
Another drug that has been on subject for the treatment of covid-19, is the antimalarial Chloroquine. Some cases have been reported for the use of this drug to vanquish this fast spreading virus.
On March 22, a Europe-wide clinical trial, called Discovery, was launched to test four experimental treatments for COVID-19, including the following compounds: remdesivir, lopinavir and ritonavir, hydroxychloroquine. The University Hospitals of Strasbourg, Alsachim's partner, are among the French hospitals selected for this experiment.
This trial will also complement the data that will be collected during another international clinical trial, called "Solidarity".
Share this new